Verona Pharma (VRNA) Expected to Announce Quarterly Earnings on Tuesday

Verona Pharma (NASDAQ:VRNA - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $41.47 million for the quarter.

Verona Pharma Stock Performance

Shares of NASDAQ VRNA traded up $0.68 during midday trading on Friday, reaching $65.46. 766,895 shares of the stock were exchanged, compared to its average volume of 1,230,417. The firm has a 50-day simple moving average of $62.40 and a two-hundred day simple moving average of $50.68. Verona Pharma has a twelve month low of $11.39 and a twelve month high of $70.40. The firm has a market cap of $5.29 billion, a price-to-earnings ratio of -34.09 and a beta of 0.16. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Roth Mkm initiated coverage on shares of Verona Pharma in a report on Friday, January 10th. They issued a "buy" rating and a $68.00 price objective for the company. Truist Financial restated a "buy" rating and set a $57.00 price objective (up from $44.00) on shares of Verona Pharma in a research report on Wednesday, January 8th. Roth Capital set a $83.00 price target on shares of Verona Pharma in a research report on Friday, February 28th. Canaccord Genuity Group increased their price objective on Verona Pharma from $44.00 to $72.00 and gave the stock a "buy" rating in a research report on Wednesday, February 12th. Finally, Wells Fargo & Company upped their price target on Verona Pharma from $74.00 to $93.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $75.43.

Insiders Place Their Bets

In related news, insider Kathleen A. Rickard sold 79,264 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $8.35, for a total value of $661,854.40. Following the completion of the sale, the insider now directly owns 2,608,976 shares of the company's stock, valued at $21,784,949.60. The trade was a 2.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.80% of the stock is currently owned by company insiders.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.